SCHEDULE: Steamboat Capital Partners Secures Medifast Board Seats

Activist investor Steamboat Capital Partners, holding 6.0% of Medifast, Inc., has reached a cooperation agreement to nominate two designees to the board and pursue cost-efficiency.

Summary

• Steamboat Capital Partners, LLC and Parsa Kiai (Reporting Persons) jointly filed a Schedule 13D regarding Medifast, Inc.
• The Reporting Persons beneficially own 657,590 shares of Medifast common stock, representing 6.0% of the outstanding shares.
• Shares were acquired for approximately $7,382,683 by clients of IA, primarily through open market purchases using working capital.
• Reporting Persons believe Medifast shares were undervalued and represent an attractive investment opportunity.
• A Cooperation Agreement was executed on March 19, 2026, between Medifast and the Steamboat Group.
• Medifast agreed to nominate seven individuals, including Steamboat's Parsa Kiai and Jeffrey Rose, for election to the Board at the 2026 Annual Meeting.
• The Steamboat Group committed to vote its shares in favor of the Agreed Nominees and other Board recommendations (with specific exceptions).
• A standstill agreement is in place, restricting certain activist actions by the Steamboat Group until three months after the 2027 Annual Meeting.
• Steamboat sent a letter to Medifast's Board on March 19, 2026, proposing financial and strategic suggestions, including cost-efficiency and right-sizing business operations.
• The letter highlighted Medifast's market capitalization of $105 million (as of March 13, 2026) being $60 million less than its current cash balance of $167 million.
• Steamboat believes a credible path exists for an operational turnaround, leading to sustainable profitable growth and substantial stock price upside.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development. While the underlying business faces significant challenges, the engagement of an activist investor and the securing of board representation often serve as catalysts for strategic review, operational improvements, and potential value unlocking, despite the inherent execution risks.

Positives

• A cooperation agreement has been reached with an activist investor, potentially avoiding a costly proxy contest.
• Two designees from Steamboat Capital Partners, Parsa Kiai and Jeffrey Rose, will be nominated to Medifast's Board, providing direct shareholder representation.
• The agreement focuses on implementing cost-efficiency efforts and right-sizing business operations to restore profitability.
• Steamboat Capital Partners believes Medifast's stock is significantly undervalued, with its $105 million market cap (as of March 13, 2026) being $60 million less than its $167 million cash balance.
• The Reporting Persons see a credible path for an operational turnaround, leading to sustainable profitable growth and substantial stock price upside.

Negatives

• Medifast faces "significant challenges given the changes in the industry," particularly in a "post-GLP-1 world."
• The public markets have "lost faith in the current prospects of Medifast's business strategy."
• Medifast has been valued below its net cash since early 2025, and this discount has increased.
• The need for "thoughtful cost-cutting and right-sizing the business operations and corporate overhead" indicates existing inefficiencies and potential for difficult restructuring.

Risks

• Significant challenges persist due to changes in the direct-selling industry, including competition from GLP-1s.
• Public market sentiment remains negative, with the company valued below its net cash.
• The operational turnaround strategy, while credible, may involve cash losses during its implementation.
• There is no assurance that the proposed cost-cutting and efficiency measures will successfully restore comparable operating margins to industry peers.
• The standstill agreement limits the Steamboat Group's ability to exert further activist pressure or pursue alternative strategies for a defined period.

Future Outlook

Reporting Persons believe Medifast's stock is significantly undervalued and there is a credible path for an operational turnaround through thoughtful cost-cutting and right-sizing business operations. This is expected to lead to sustainable profitable growth and substantial stock price upside. They anticipate further discussions with Medifast's management and Board covering profitability, strategic direction, shareholder value, and governance.

Management Comments

• "We believe that the company faces some significant challenges given the changes in the industry, but there is a credible path for an operational turnaround, and in that case the company's stock is significantly undervalued."
• "The public markets have lost faith in the current prospects of Medifast's business strategy by valuing the company (with its current $105 million market cap, as of March 13, 2026) at $60 million less than its current cash balance ($167 million)."
• "We believe that through thoughtful cost-cutting and right-sizing the business operations and corporate overhead, the company would be able to compete profitably even under the new realities of the direct-selling industry in a post-GLP-1 world."
• "We believe that an emphasis on efficiency across technology, corporate and other areas would return the company to operational profitability."
• "Even with very conservative valuation multiples on its operating business and inclusive of the cash losses required to achieve the turnaround, we believe that Medifast's stock price could have substantial upside."

Industry Context

StockSavvy.ai notes that the direct-selling industry, particularly in health and wellness, is undergoing significant transformation, partly due to the emergence of GLP-1 weight-loss drugs. Medifast's acknowledged challenges and the activist investor's focus on cost-cutting and operational efficiency reflect a broader industry trend where companies must adapt to changing consumer preferences and competitive landscapes to maintain profitability and regain investor confidence.

Comparison to Industry Standards

• Steamboat Capital Partners believes a peer benchmarking exercise with other publicly traded direct-selling companies demonstrates that profitability is achievable for Medifast, even with competitive challenges from GLP-1s and other industry pressures.
• The Reporting Persons believe there is a credible path for Medifast to achieve a comparable operating margin as its peers through efficiency efforts.
• A comparison of Medifast's current cost structure with its "Take Shape For Life" segment in 2015, when the business was of roughly similar size, is used to illustrate the potential for corporate streamlining.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for increased shareholder value through strategic changes, cost-cutting, and improved governance due to activist investor representation.
• Management/Board: Increased scrutiny and pressure to perform, with new board members bringing an activist perspective focused on efficiency and profitability.
• Employees: Potential for operational streamlining and cost-cutting initiatives could lead to workforce adjustments.
• Customers/Suppliers: No direct impact mentioned, but improved company performance could indirectly benefit relationships.

Next Steps

• Medifast will nominate Parsa Kiai and Jeffrey Rose, along with five other individuals, for election to the Board at the 2026 Annual Meeting.
• The Company currently intends to hold the 2026 Annual Meeting on May 19, 2026, and will use reasonable best efforts to hold it no later than June 19, 2026.
• The Reporting Persons expect to have further discussions with Medifast's management and Board regarding profitability, strategic direction, shareholder value, and governance.
• The Reporting Persons will continuously review their investment and may take further actions, such as purchasing or selling shares, or making additional proposals, consistent with the Cooperation Agreement.
• Medifast will nominate the Steamboat Designees for election at the 2027 Annual Meeting, provided the Steamboat Group maintains at least 2% beneficial ownership.
• The Company and the Investors will jointly issue a mutually agreeable press release announcing the terms of the Cooperation Agreement.

Key Dates

Recommendation

The filing reveals Medifast is facing significant industry challenges, reflected in its market capitalization being substantially below its cash balance and public markets having 'lost faith.' While the cooperation agreement with Steamboat Capital Partners and the addition of two activist-backed directors to the board are positive steps towards initiating an operational turnaround and addressing undervaluation, the path to sustainable profitability involves 'thoughtful cost-cutting' and 'right-sizing,' indicating a period of execution risk and potential disruption. A 'hold' recommendation is appropriate as the stock's future performance hinges on the successful implementation of these strategic changes amidst a challenging industry backdrop.

Keywords

Medifast, Steamboat Capital Partners, Schedule 13D, Shareholder Activism, Board Nomination, Corporate Governance, Cost Efficiency, Undervaluation, Direct Selling, GLP-1, Investment Adviser